Soluble CD83 Levels Reduced in NMOSD and Relapsing MOGAD, Pointing to Potential Biomarker
Written by
Neurology Live
Published
0
comments
0
min
New findings highlight the potential of sCD83 as a prognostic biomarker in NMOSD and MOGAD, supporting its role as both a therapeutic target and a marker of treatment response in these autoimmune diseases.